Thermo Fisher Scientific
Proteomics utilizes a comprehensive set of technologies to detect, quantify and characterize proteins to assess normal biology and perturbations that cause diseases. Research clinicians wish to access leverage the analytical power of proteomics (and LCMS in general) to better understand disease and potentially provide better therapeutic solutions in medical care, but are generally not formally trained in LCMS technology.
Lorne Taylor, Manager of the Clinical Proteomics Platform (serves 5 separate on-site hospitals with over 2,100 research staff and 550 researchers) at the Research Institute of the McGill University Health Center (RI-MUHC) in Montreal serves as the bridge between the research bench and the research clinicians.
In this webinar he will show how combining small molecule quantitation with proteomics helps research clinicians to get a better picture of the biomolecular flux and changes in wellness and disease.
For research use only. Not for use in diagnostic procedures.
Lorne Taylor, Manager, Clinical Proteomics Platform
Research Institute of the McGill University Health Center (RI-MUHC)
Lorne has been involved with proteomics for over 25 years within the mass spectrometry industry, in academia and with biotech startups. Prior to directing the Ontario Proteomics Methods Center at Mt Sinai Hospital in Toronto for 10 years, he had worked designing, testing and implementing proteomics (and other) technologies around the world for the global pharmaceuticals industry, biotechnology and academic institutions. Currently Lorne manages the Clinical Proteomics Platform at the Research Institute of the McGill University Health Center (RI-MUHC) in Montreal which serves five separate hospitals and an associated research institute with over 2100 research staff and 550 research labs.
* Required field